for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cerus Corporation

CERS.OQ

Latest Trade

4.32USD

Change

-0.02(-0.46%)

Volume

176,508

Today's Range

4.28

 - 

4.42

52 Week Range

3.96

 - 

6.88

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
4.34
Open
4.35
Volume
176,508
3M AVG Volume
18.71
Today's High
4.42
Today's Low
4.28
52 Week High
6.88
52 Week Low
3.96
Shares Out (MIL)
142.01
Market Cap (MIL)
609.00
Forward P/E
-8.71
Dividend (Yield %)
--

Latest Developments

More

Cerus Reports Q3 Loss Per Share Of $0.13

Cerus Corp Reports Q2 Loss Per Share $0.13

Cerus Corporation Q1 Loss Per Share $0.14

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cerus Corporation

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company's INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company's INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company's INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.

Industry

Biotechnology & Drugs

Contact Info

1220 Concord Ave Ste 600

+1.925.2886000

http://www.cerus.com/

Executive Leadership

Daniel N. Swisher

Independent Chairman of the Board

William M. Greenman

President, Chief Executive Officer, Director

Kevin Dennis Green

Chief Financial Officer, Vice President - Finance

Carol M. Moore

Senior Vice President - Regulatory Affairs, Quality and Clinical

William Moore

Senior Vice President of Manufacturing Operations and Supply Chain

Key Stats

1.33 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.1K

2018

0.1K

2019(E)

0.1K
EPS (USD)

2016

-0.620

2017

-0.560

2018

-0.440

2019(E)

-0.503
Price To Earnings (TTM)
--
Price To Sales (TTM)
6.96
Price To Book (MRQ)
10.14
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
72.96
LT Debt To Equity (MRQ)
64.75
Return on Investment (TTM)
-59.43
Return on Equity (TTM)
-43.25

Latest News

Latest News

BRIEF-Cerus Corp Reports Q1 Loss Per Share $0.11

* Q1 EARNINGS PER SHARE VIEW $-0.12 -- THOMSON REUTERS I/B/E/S

BRIEF-Cerus Announces Health Canada Approval Of The Intercept Blood System For Platelets

* CERUS ANNOUNCES HEALTH CANADA APPROVAL OF THE INTERCEPT BLOOD SYSTEM FOR PLATELETS Source text for Eikon: Further company coverage:

BRIEF-Cerus’ Redes Phase 3 Red Blood Cell Study Expands Into The Continental U.S.

* ’ REDES PHASE 3 RED BLOOD CELL STUDY EXPANDS INTO THE CONTINENTAL U.S.

BRIEF-Cerus Announces The Fourth Biologics License Application Approval For A U.S. Blood Center Customer

* CERUS ANNOUNCES THE FOURTH BIOLOGICS LICENSE APPLICATION (BLA) APPROVAL FOR A U.S. BLOOD CENTER CUSTOMER

BRIEF-Cerus Corp Reports Q4 Loss Per Share $0.10

* ORATION REPORTS RECORD FOURTH QUARTER AND YEAR END 2017 RESULTS

BRIEF-Cerus Announces Pricing Of Public Offering Of Common Stock

* CERUS CORP - PRICING OF PUBLIC OFFERING OF ITS COMMON STOCK FOR PROCEEDS OF $50.0 MILLION, BEFORE DEDUCTING ESTIMATED OFFERING EXPENSES PAYABLE BY CERUS Source text for Eikon: Further company coverage:

BRIEF-Cerus Announces Public Offering Of Common Stock

* CERUS CORP - COMMENCED A REGISTERED UNDERWRITTEN PUBLIC OFFERING OF $50.0 MILLION OF ITS COMMON STOCK Source text for Eikon: Further company coverage:

BRIEF-Cerus - Chronic Anemia Phase 3 Study Met Primary Efficacy And Safety Endpoints

* CERUS REPORTS POSITIVE TOP-LINE RESULTS FROM CHRONIC ANEMIA PHASE 3 STUDY EVALUATING INTERCEPT RED BLOOD CELLS IN THALASSEMIA PATIENTS

BRIEF-Cerus Corp Expects Full Year 2017 Product Revenue To Be $43.6 Million

* CERUS CORP - CERUS' UNAUDITED PRELIMINARY PRODUCT REVENUE FOR Q4 OF 2017 WAS $16.2 MILLION

BRIEF-Cerus receives IDE approval to initiate phase iii recepi study

* Cerus Corporation receives IDE approval to initiate phase iii recepi study Source text for Eikon: Further company coverage:

BRIEF-Cerus Corp reports Q3 loss per share $0.12

* Q3 earnings per share view $-0.15 -- Thomson Reuters I/B/E/S

BRIEF-Cerus and Kedrion Biopharma enter distribution agreement for full INTERCEPT blood system portfolio

* Cerus and Kedrion Biopharma enter distribution agreement for the full INTERCEPT blood system portfolio in Italy

BRIEF-Cerus announces agreement with transfusion Center of the Community of Madrid

* Cerus announces agreement with transfusion Center of the Community of Madrid

BRIEF-CERUS ANNOUNCES NATIONAL GERMAN REIMBURSEMENT FOR PATHOGEN INACTIVATED PLATELETS

* CERUS SAYS INSTITUTE FOR HOSPITAL REMUNERATION SYSTEM IN GERMANY WILL INCLUDE PATHOGEN-INACTIVATED PLATELETS FOR NATIONAL REIMBURSEMENT STARTING JAN 1, 2018 Source text for Eikon: Further company coverage:

BRIEF-Cerus Corp files for mixed shelf of up to $250 mln - SEC filing

* Cerus Corp files for mixed shelf of up to $250 million - SEC filing Source text: (http://bit.ly/2wfbOni) Further company coverage:

BRIEF-Cerus Q2 loss per share $0.16

* Q2 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S

BRIEF-Cerus enters into $40 mln amended growth capital agreement

* Cerus enters into $40 million amended growth capital agreement

BRIEF-Cerus expands agreement with French National Blood Service

* Cerus announces expanded supply agreement with french national blood service

BRIEF-Cerus provides update on U.S. Platelet additive solution supply

* Cerus provides update on U.S. Platelet additive solution (pas) supply

BRIEF-Cerus provides U.S. business update

* A pending platelet additive solution shortage is expected to impact some U.S. blood centers producing intercept platelets

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up